galantamine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1272 357-70-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • galantamine
  • galantamin
  • galantamina
  • lycoremin
  • lycoremine
  • galanthamine
  • (-)-Galantamine
  • (-)-Galanthamine
  • galantamine hydrobromide
  • galanthamine hydrobromide
A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders.
  • Molecular weight: 287.36
  • Formula: C17H21NO3
  • CLOGP: 1.02
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 41.93
  • ALOGS: -2.23
  • ROTB: 1

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
16 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 10 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 20 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.45 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 99 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 2.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 5.60 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.83 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 5.30 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Feb. 28, 2001 FDA JANSSEN PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Orthostatic hypotension 932.25 38.03 281 6376 29200 50569267
Sedation complication 929.48 38.03 218 6439 8548 50589919
Creatinine renal clearance decreased 913.54 38.03 228 6429 11653 50586814
Sedation 874.90 38.03 270 6387 30340 50568127
Cognitive disorder 836.51 38.03 285 6372 43838 50554629
Blood calcium decreased 779.09 38.03 226 6431 20480 50577987
Balance disorder 705.92 38.03 285 6372 70305 50528162
Depressed level of consciousness 628.65 38.03 241 6416 51712 50546755
Mobility decreased 481.31 38.03 226 6431 79722 50518745
Fall 456.55 38.03 364 6293 334568 50263899
Constipation 442.28 38.03 284 6373 185424 50413043
Hypotension 403.88 38.03 294 6363 235175 50363292
Toxicity to various agents 292.23 38.03 233 6424 212266 50386201
Pain 96.60 38.03 225 6432 578678 50019789
Drug ineffective 77.18 38.03 9 6648 819324 49779143
Product dispensing error 55.85 38.03 26 6631 8865 50589602
Pleurothotonus 52.29 38.03 15 6642 1286 50597181
Fatigue 49.36 38.03 16 6641 707585 49890882
Marasmus 46.79 38.03 11 6646 429 50598038

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Fall 62.14 22.60 82 2872 177096 29394477
Dysphagia 37.37 22.60 36 2918 54890 29516683
Post-traumatic stress disorder 35.58 22.60 11 2943 1611 29569962
Compartment syndrome 34.97 22.60 12 2942 2440 29569133
Fracture 33.81 22.60 15 2939 6038 29565535
Agitation 31.86 22.60 32 2922 51272 29520301
Hallucination 27.96 22.60 28 2926 44684 29526889
Increased bronchial secretion 27.56 22.60 9 2945 1572 29570001
Aggression 25.49 22.60 24 2930 35517 29536056
Miosis 24.07 22.60 13 2941 7996 29563577
Coombs negative haemolytic anaemia 23.91 22.60 5 2949 150 29571423
Loss of consciousness 23.86 22.60 33 2921 74023 29497550
Bradycardia 23.82 22.60 31 2923 65598 29505975
Hallucination, visual 23.41 22.60 16 2938 14999 29556574
Cholinergic syndrome 22.96 22.60 6 2948 480 29571093
Pneumonia aspiration 22.95 22.60 23 2931 36714 29534859

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sedation complication 984.79 28.87 238 8636 10116 64479742
Creatinine renal clearance decreased 925.77 28.87 242 8632 14179 64475679
Orthostatic hypotension 844.83 28.87 295 8579 46443 64443415
Sedation 839.85 28.87 285 8589 41177 64448681
Cognitive disorder 830.85 28.87 304 8570 54783 64435075
Blood calcium decreased 780.30 28.87 240 8634 25314 64464544
Balance disorder 690.21 28.87 299 8575 83627 64406231
Depressed level of consciousness 604.19 28.87 270 8604 81166 64408692
Mobility decreased 503.66 28.87 242 8632 85598 64404260
Fall 501.63 28.87 430 8444 416396 64073462
Constipation 409.02 28.87 299 8575 229038 64260820
Hypotension 326.53 28.87 326 8548 380648 64109210
Toxicity to various agents 226.15 28.87 263 8611 363250 64126608
Pain 119.07 28.87 245 8629 553266 63936592
Drug ineffective 59.30 28.87 21 8853 840226 63649632
Marasmus 48.10 28.87 13 8861 855 64489003
Pleurothotonus 43.20 28.87 15 8859 2287 64487571
Bradycardia 33.39 28.87 59 8815 118160 64371698
Poriomania 31.70 28.87 7 8867 196 64489662
Agitation 31.53 28.87 49 8825 88318 64401540
Fracture 29.92 28.87 23 8851 18732 64471126
Loss of consciousness 29.66 28.87 64 8810 148301 64341557
Fatigue 29.42 28.87 36 8838 748694 63741164

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06DA04 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTI-DEMENTIA DRUGS
Anticholinesterases
FDA MoA N0000000177 Cholinesterase Inhibitors
MeSH PA D002491 Central Nervous System Agents
MeSH PA D018678 Cholinergic Agents
MeSH PA D002800 Cholinesterase Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018697 Nootropic Agents
MeSH PA D010277 Parasympathomimetics
MeSH PA D018373 Peripheral Nervous System Agents
FDA EPC N0000175723 Cholinesterase Inhibitor
CHEBI has role CHEBI:37733 EC 3.1.1.8 inhibitor
CHEBI has role CHEBI:38323 cholinergic drugs
CHEBI has role CHEBI:38462 acetylcholinesterase inhibitors
CHEBI has role CHEBI:74530 curare poisoning antidote
CHEBI has role CHEBI:76924 plant metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Alzheimer's disease indication 26929004 DOID:10652
Diffuse Lewy body disease off-label use 80098002
Moderate to Severe Alzheimer's Type Dementia off-label use
Peptic ulcer contraindication 13200003 DOID:750
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Gastrointestinal ulcer contraindication 40845000
Bradycardia contraindication 48867003
Duodenal ulcer disease contraindication 51868009 DOID:1724
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Epilepsy contraindication 84757009 DOID:1826
Kidney disease contraindication 90708001 DOID:557
Asthma contraindication 195967001 DOID:2841
Atrioventricular block contraindication 233917008 DOID:0050820
Disease of liver contraindication 235856003 DOID:409
Bladder outflow obstruction contraindication 236645006
Congenital long QT syndrome contraindication 442917000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.14 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Acetylcholinesterase Enzyme INHIBITOR Ki 7.21 CHEMBL CHEMBL
Cholinesterase Enzyme Ki 6.72 CHEMBL
Acetylcholinesterase Enzyme IC50 6.44 CHEMBL
Acetylcholinesterase Enzyme IC50 5.60 CHEMBL
Butyrylcholinesterase; Protein Bche Enzyme IC50 5.23 CHEMBL
Acetylcholinesterase Enzyme IC50 6.27 CHEMBL
Acetylcholinesterase Enzyme Ki 6.37 CHEMBL
Acetylcholinesterase Enzyme IC50 5.06 CHEMBL
Butyrylcholinesterase Enzyme Ki 5.10 CHEMBL
Cholinesterase Enzyme Ki 5.03 CHEMBL

External reference:

IDSource
4021250 VUID
N0000148691 NUI
D02173 KEGG_DRUG
1953-04-4 SECONDARY_CAS_RN
4021250 VANDF
4021251 VANDF
C0016967 UMLSCUI
CHEBI:42944 CHEBI
GNT PDB_CHEM_ID
CHEMBL659 ChEMBL_ID
DB00674 DRUGBANK_ID
CHEMBL1555 ChEMBL_ID
D005702 MESH_DESCRIPTOR_UI
9651 PUBCHEM_CID
6693 IUPHAR_LIGAND_ID
1392 INN_ID
0D3Q044KCA UNII
4637 RXNORM
147848 MMSL
15913 MMSL
d04750 MMSL
007026 NDDF
007027 NDDF
129482002 SNOMEDCT_US
323377002 SNOMEDCT_US
395727007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Galantamine Hydrobromide HUMAN PRESCRIPTION DRUG LABEL 1 0054-0137 SOLUTION 4 mg ORAL ANDA 24 sections
Galantamine HUMAN PRESCRIPTION DRUG LABEL 1 0591-3496 CAPSULE, EXTENDED RELEASE 8 mg ORAL ANDA 25 sections
Galantamine HUMAN PRESCRIPTION DRUG LABEL 1 0591-3496 CAPSULE, EXTENDED RELEASE 8 mg ORAL ANDA 25 sections
Galantamine HUMAN PRESCRIPTION DRUG LABEL 1 0591-3497 CAPSULE, EXTENDED RELEASE 16 mg ORAL ANDA 25 sections
Galantamine HUMAN PRESCRIPTION DRUG LABEL 1 0591-3497 CAPSULE, EXTENDED RELEASE 16 mg ORAL ANDA 25 sections
Galantamine HUMAN PRESCRIPTION DRUG LABEL 1 0591-3498 CAPSULE, EXTENDED RELEASE 24 mg ORAL ANDA 25 sections
Galantamine HUMAN PRESCRIPTION DRUG LABEL 1 0591-3498 CAPSULE, EXTENDED RELEASE 24 mg ORAL ANDA 25 sections
Galantamine HUMAN PRESCRIPTION DRUG LABEL 1 0904-7104 TABLET, FILM COATED 4 mg ORAL ANDA 26 sections
galantamine hydrobromide HUMAN PRESCRIPTION DRUG LABEL 1 10147-0881 TABLET, FILM COATED 4 mg ORAL NDA 27 sections
galantamine hydrobromide HUMAN PRESCRIPTION DRUG LABEL 1 10147-0882 TABLET, FILM COATED 8 mg ORAL NDA 27 sections
galantamine hydrobromide HUMAN PRESCRIPTION DRUG LABEL 1 10147-0883 TABLET, FILM COATED 12 mg ORAL NDA 27 sections
galantamine hydrobromide HUMAN PRESCRIPTION DRUG LABEL 1 10147-0891 CAPSULE, EXTENDED RELEASE 8 mg ORAL NDA 27 sections
galantamine hydrobromide HUMAN PRESCRIPTION DRUG LABEL 1 10147-0892 CAPSULE, EXTENDED RELEASE 16 mg ORAL NDA 27 sections
galantamine hydrobromide HUMAN PRESCRIPTION DRUG LABEL 1 10147-0893 CAPSULE, EXTENDED RELEASE 24 mg ORAL NDA 27 sections
RAZADYNE HUMAN PRESCRIPTION DRUG LABEL 1 21695-184 TABLET, FILM COATED 8 mg ORAL NDA 20 sections
RAZADYNE HUMAN PRESCRIPTION DRUG LABEL 1 21695-591 TABLET, FILM COATED 12 mg ORAL NDA 20 sections
Galantamine hydrobromide HUMAN PRESCRIPTION DRUG LABEL 1 43353-984 CAPSULE, EXTENDED RELEASE 16 mg ORAL ANDA 20 sections
Galantamine Hydrobromide Human Prescription Drug Label 1 47335-835 CAPSULE, EXTENDED RELEASE 8 mg ORAL ANDA 25 sections
Galantamine Hydrobromide Human Prescription Drug Label 1 47335-836 CAPSULE, EXTENDED RELEASE 16 mg ORAL ANDA 25 sections
Galantamine Hydrobromide Human Prescription Drug Label 1 47335-837 CAPSULE, EXTENDED RELEASE 24 mg ORAL ANDA 25 sections
RAZADYNE HUMAN PRESCRIPTION DRUG LABEL 1 50458-387 CAPSULE, EXTENDED RELEASE 8 mg ORAL NDA 26 sections
RAZADYNE HUMAN PRESCRIPTION DRUG LABEL 1 50458-388 CAPSULE, EXTENDED RELEASE 16 mg ORAL NDA 26 sections
RAZADYNE HUMAN PRESCRIPTION DRUG LABEL 1 50458-389 CAPSULE, EXTENDED RELEASE 24 mg ORAL NDA 26 sections
RAZADYNE HUMAN PRESCRIPTION DRUG LABEL 1 50458-396 TABLET, FILM COATED 4 mg ORAL NDA 26 sections
RAZADYNE HUMAN PRESCRIPTION DRUG LABEL 1 50458-397 TABLET, FILM COATED 8 mg ORAL NDA 26 sections
RAZADYNE HUMAN PRESCRIPTION DRUG LABEL 1 50458-398 TABLET, FILM COATED 12 mg ORAL NDA 26 sections
Galantamine Hydrobromide HUMAN PRESCRIPTION DRUG LABEL 1 51990-111 TABLET, FILM COATED 4 mg ORAL NDA 26 sections
Galantamine Hydrobromide HUMAN PRESCRIPTION DRUG LABEL 1 51990-112 TABLET, FILM COATED 8 mg ORAL NDA 26 sections
Galantamine Hydrobromide HUMAN PRESCRIPTION DRUG LABEL 1 51990-113 TABLET, FILM COATED 12 mg ORAL NDA 26 sections
Galantamine Human Prescription Drug Label 1 57237-049 TABLET, FILM COATED 4 mg ORAL ANDA 25 sections